Factbox-Amgen-Horizon deal joins mega mergers facing regulatory heat
(Reuters) – A U.S. antitrust regulator said on Tuesday it will sue to stop Amgen’s $27.8 billion deal for Horizon Therapeutics Plc, as it would give Amgen “monopoly positions” in treatments for thyroid eye disease and chronic refractory gout. Here is a list of some mergers that recently faced strong antitrust scrutiny around the world:…